In-vitro vortex type uniformly-mixed carbon dioxide chemotherapeutic drug aerosol generation system

Abstract

The invention relates to an in-vitro vortex type uniformly-mixed carbon dioxide chemotherapeutic drug aerosol generation system which comprises a drug delivery pipeline, a drug atomizer, an abdominal cavity and a carbon dioxide pneumoperitoneum machine, one end of the drug delivery pipeline is connected with the drug atomizer, and the other end of the drug delivery pipeline is connected with the abdominal cavity; a first air supply pipeline is connected between the carbon dioxide pneumoperitoneum machine and the dosing pipeline, and a second air supply pipeline is connected between the carbon dioxide pneumoperitoneum machine and the abdominal cavity; and a vortex generator is arranged on the dosing pipeline. According to the in-vitro vortex type uniformly-mixed carbon dioxide chemotherapeutic drug aerosol generation system, carbon dioxide chemotherapeutic drug aerosol with smaller mist particles and uniform distribution can be provided, a small amount of anti-cancer drugs can be more effectively conveyed to cancer cells, the dosage of the chemotherapeutic drugs is only 10-30% of that of traditional intraperitoneal hyperthermic perfusion chemotherapy (HIPEC), the tissue penetrating power of the aerosol is high, and the anti-cancer effect is good. The pharmaceutical composition can improve pharmacokinetics, greatly reduce the use amount of chemotherapeutic drugs, reduce toxic and side effects and reduce treatment cost, and is efficient, convenient and safe.

Description

Technical Field

[0001] The invention relates to the field of medical facilities, in particular to an in vitro vortex-mixed carbon dioxide chemotherapy drug aerosol generation system. Background Art

[0002] The traditional way to inhibit free peritoneal cancer cells and peritoneal cancer is to use hyperthermic intraperitoneal chemotherapy (HIPEC), which is to precisely maintain the temperature of the perfusion solution containing chemotherapy drugs, circulate and perfuse, fill the abdominal cavity and maintain it for a period of time to treat primary and secondary peritoneal cancer, or prevent peritoneal metastasis. The disadvantages of this chemotherapy method are that the depth of chemotherapy drugs penetrating tissues is limited, the amount of drugs used is large, the toxic side effects are large, the treatment cost is high, and the efficacy is still controversial. Summary of the invention

[0003] In view of this, the purpose of the present invention is to provide an in vitro vortex-mixed carbon dioxide chemotherapy drug aerosol generation system, which can greatly reduce the amount of chemotherapy drugs used, reduce toxic side effects, and reduce treatment costs.

[0004] The present invention is implemented by the following scheme: an in vitro vortex-mixed carbon dioxide chemotherapy drug aerosol generation system, comprising a drug administration pipeline, a drug nebulizer, an abdominal cavity and a carbon dioxide insufflating machine, wherein one end of the drug administration pipeline is connected to the drug nebulizer, and the other end is connected to the abdominal cavity; a first air supply pipeline is connected between the carbon dioxide insufflating machine and the drug administration pipeline, and a second air supply pipeline is connected between the carbon dioxide insufflating machine and the abdominal cavity; a vortex generator is provided on the drug administration pipeline.

[0005] Furthermore, the drug delivery pipeline is provided with a one-way valve A, a ball valve A and a heater.

[0006] Furthermore, a ball valve B and a one-way valve C are provided on the first air supply pipeline; a ball valve C and a one-way valve B are provided on the second air supply pipeline, and the first air supply pipeline is connected to the pipe section between the one-way valve A and the ball valve A on the drug delivery pipeline.

[0007] Furthermore, the vortex generator includes a cylinder, a spiral channel is provided in the cylinder, an air inlet chamber is provided inside the rear end of the cylinder and is communicated with the rear end of the spiral channel, an air outlet chamber is provided inside the front end of the cylinder and is communicated with the front end of the spiral channel, the rear end of the cylinder is provided with a main inlet communicated with the air inlet chamber, and the front end is provided with a main outlet communicated with the air outlet chamber.

[0008] Furthermore, the rear end side of the cylinder of the vortex generator is provided with a first circulation inlet connected to the air inlet chamber, and the front end side is provided with a circulation outlet connected to the air outlet chamber. A circulation pipe is connected between the circulation outlet and the circulation inlet, and the circulation pipe is provided with a ball valve D, a circulation pump and a one-way valve D.

[0009] Furthermore, the drug administration pipeline and the first air supply pipeline are connected through a cache chamber, and a chamber cover is provided on the upper part of the cache chamber. The chamber cover of the cache chamber is rotatably connected to a stirring shaft extending into the cache chamber, and a stirring impeller is connected to the lower end of the stirring shaft; an exhaust pipe and a pressure gauge are also connected to the chamber cover of the cache chamber, and a heater is provided on the outer side of the cache chamber.

[0010] Furthermore, the bottom of the cache bin is provided with a first drug outlet and a second drug outlet, and the cover of the cache bin is provided with a first drug inlet and a second drug inlet. The first drug inlet and the first drug outlet are used for connecting the drug delivery pipeline in series, and the second drug inlet is connected to the first air supply pipeline; the second drug outlet is connected to a drug outlet pipe, and a ball valve E is provided on the drug outlet pipe.

[0011] Furthermore, the air extraction pipe is connected to the vacuum extraction device, and a valve is provided on the air extraction pipe.

[0012] Furthermore, the drug nebulizer adopts a compression nebulizer, and the compressed gas inlet of the compression nebulizer is connected to a carbon dioxide high-pressure air pipe; a first drug inlet is provided on the side of the compression nebulizer, and the first drug inlet is connected to the drug storage tank through a drug supply pipe, and a peristaltic pump and a one-way valve E are provided on the drug supply pipe.

[0013] Furthermore, the abdominal cavity is connected to an exhaust pipeline, and the exhaust pipeline is connected to an exhaust safety valve and an exhaust gas treatment system.

[0014] Compared with the prior art, the present invention has the following beneficial effects: the in vitro vortex-mixed carbon dioxide chemotherapy drug aerosol generation system of the present invention can provide carbon dioxide chemotherapy drug aerosols with smaller mist particles and uniform distribution, and more effectively deliver a small amount of anti-cancer drugs to cancer cells. The amount of chemotherapy drugs used is only 10-30% of that of traditional intraperitoneal hyperthermic perfusion chemotherapy (HIPEC). The aerosol has strong tissue penetration, which can improve pharmacokinetics, greatly reduce the amount of chemotherapy drugs used, reduce toxic side effects, and reduce treatment costs. It is efficient, convenient, and safe.

[0015] In order to make the objectives, technical solutions and advantages of the present invention more clearly understood, the present invention will be further described in detail below through specific embodiments and related drawings. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 It is a schematic diagram of the structure of the first embodiment of the present invention; Figure 2 This is a schematic diagram of the structure of the second embodiment of the present invention; Explanation of the numbers in the figure: 1-drug administration pipeline, 2-drug atomizer, 3-abdominal cavity, 4-first air supply pipeline, 5-second air supply pipeline, 6-exhaust pipeline, 7-ball valve A, 8-heater, 9-ball valve B, 10-check valve C, 11-ball valve C, 12-check valve B, 13-check valve A, 14-vortex generator, 15-spiral channel, 16-air inlet chamber, 17-air outlet chamber, 18-circulation pipe, 19-ball valve D, 20-circulation pump, 21-check valve D, 22-valve, 23-buffer bin, 24-stirring shaft, 25-stirring impeller, 26-stirring motor, 27-exhaust pipe, 28-pressure gauge, 29-drug outlet pipe, 30-carbon dioxide high-pressure air pipe, 31-peristaltic pump, 32-check valve E, 33-exhaust safety valve, 34-waste gas treatment system, 35-drug storage tank, 36-vacuum device. DETAILED DESCRIPTION

[0017] It should be noted that the following detailed descriptions are exemplary and are intended to provide further explanation of the present application. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present application belongs.

[0018] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit the exemplary embodiments according to the present application. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should be understood that when the terms "comprise" and / or "include" are used in this specification, it indicates the presence of features, steps, operations, devices, components and / or combinations thereof.

[0019] Embodiment 1: Figure 1As shown, an in vitro vortex-mixed carbon dioxide chemotherapy drug aerosol generation system includes a drug administration pipeline 1, a drug nebulizer 2, an abdominal cavity 3 and a carbon dioxide insufflator. One end of the drug administration pipeline 1 is connected to the drug nebulizer and the other end is connected to the abdominal cavity 3; a first air supply pipeline 4 is connected between the carbon dioxide insufflator and the drug administration pipeline, and a second air supply pipeline 5 is connected between the carbon dioxide insufflator and the abdominal cavity. The system can be used for actual treatment or experimental research; during surgery, the carbon dioxide of the carbon dioxide insufflator directly enters the abdominal cavity through the second air supply pipeline 5 and maintains a pressure of 12-15 mmHg; during intraperitoneal chemotherapy, the mixed aerosol on the drug administration pipeline 1 directly enters the abdominal cavity. The carbon dioxide insufflator appropriately replenishes air through the second air supply pipeline 5 to maintain the working pressure of the intraperitoneal aerosol at 12-15 mmHg. The abdominal cavity 3 can be a human abdominal cavity or an in vitro simulated abdominal cavity. The system can perform warm carbon dioxide chemotherapy drug aerosol administration in the abdominal cavity. Providing aerosols of chemotherapy drugs with smaller and more evenly distributed carbon dioxide mist particles, according to different usage scenarios, more effectively delivers a small amount of anticancer drugs to cancer cells, thereby maximizing the inhibition of free peritoneal cancer cells and peritoneal cancer. The amount of chemotherapy drugs used is only 10-30% of traditional hyperthermic intraperitoneal chemotherapy (HIPEC). Aerosols have strong tissue penetration and can improve pharmacokinetics, which can greatly reduce the amount of chemotherapy drugs used, reduce treatment costs, and reduce toxic side effects. In addition, the smaller the mist particles, the better the laparoscopic field of view, which can achieve intraperitoneal pressurized aerosol chemotherapy during laparoscopic tumor resection surgery, inhibit the free peritoneal cancer cells that may be generated during the operation, and prevent postoperative tumor implantation, which is efficient, convenient, and safe.

[0020] In this embodiment, the drug administration pipeline 1 is provided with a one-way valve A13, a ball valve A7 and a heater 8. The heater can be used to adjust the temperature of the carbon dioxide chemotherapy drug aerosol entering the abdominal cavity to 37-43°C.

[0021] In this embodiment, a ball valve B9 and a one-way valve C10 are provided on the first air supply pipeline; a ball valve C11 and a one-way valve B12 are provided on the second air supply pipeline, and the first air supply pipeline is connected to the pipe section between the one-way valve A and the ball valve A on the drug delivery pipeline.

[0022] In this embodiment, the drug nebulizer adopts a compression nebulizer, and the compressed gas inlet of the compression nebulizer is connected to a carbon dioxide high-pressure gas pipe 30; the side of the compression nebulizer is provided with a first drug inlet for adding liquid chemotherapy drugs; the first drug inlet is connected to a drug storage tank 35 through a drug supply pipe, and the drug supply pipe is provided with a peristaltic pump 31 and a one-way valve E32. The compression nebulizer uses high-pressure carbon dioxide gas instead of air. According to the Venturi injection principle, compressed carbon dioxide forms a high-speed airflow through a small pipe orifice. The negative pressure generated drives liquid or other fluids to be sprayed onto a diaphragm or baffle. Under high-speed impact, the droplets splash around and become extremely fine mist and spray out to the outside. The relatively large droplets are liquefied and returned to the liquid reservoir for recycling.

[0023] In this embodiment, the abdominal cavity is connected to an exhaust pipeline 6, to which an exhaust safety valve 33 and a waste gas treatment system 34 are connected. After the administration is completed, the gas in the abdominal cavity is discharged through the exhaust pipeline after treatment; the waste gas treatment system 34 is in the prior art, and its structure and principle are not elaborated in detail here.

[0024] In this embodiment, the abdominal cavity is connected to the drug administration circuit and the second air supply circuit respectively through an air inlet trocar, and the abdominal cavity is connected to the exhaust circuit through an air outlet trocar; the air inlet trocar and the air outlet trocar are provided with valves for controlling opening and closing.

[0025] In this embodiment, the medication pipeline 1 and the first air supply pipeline 4 are connected via a three-way pipe A; the first air supply pipeline 4 and the second air supply pipeline 5 are also connected to the carbon dioxide insufflator via a three-way pipe B.

[0026] In this embodiment, a vortex generator 14 is provided on the drug delivery pipeline, and the vortex generator 14 is arranged between the one-way valve A13 and the three-way pipe A.

[0027] In this embodiment, the vortex generator 14 includes a cylinder, a spiral channel 15 is provided in the cylinder, an air inlet chamber 16 communicating with the rear end of the spiral channel is provided inside the rear end of the cylinder, an air outlet chamber 17 communicating with the front end of the spiral channel is provided inside the front end of the cylinder, and a main inlet communicating with the air inlet chamber is provided at the rear end of the cylinder, and a main outlet communicating with the air outlet chamber is provided at the front end. Since the interior of the vortex generator is a narrow space that advances in a spiral, after the chemotherapy drug aerosol enters the spiral channel 15, a fully mixed aerosol vortex is formed; part of the atomized liquid medicine is liquefied due to impacting the inner wall of the vortex generator, and the high-pressure carbon dioxide can impact the liquefied liquid medicine on the inner wall again to re-form small droplets of aerosol. During intraperitoneal chemotherapy, the fully mixed aerosol vortex directly enters the abdominal cavity through the drug delivery pipeline 1. The carbon dioxide pneumoperitoneum machine appropriately replenishes air through the second air supply pipeline 5 to maintain the working pressure of the intraperitoneal aerosol at 12-15 mmHg.

[0028] In this embodiment, the rear end side of the cylinder of the vortex generator 14 is provided with a first circulation inlet communicating with the air inlet chamber, and the front end side is provided with a circulation outlet communicating with the air outlet chamber, and a circulation pipe 18 is connected between the circulation outlet and the circulation inlet, and the circulation pipe is provided with a ball valve D19, a circulation pump 20 and a one-way valve D21. The vortex generator 14 can be internally circulated through the circulation pipe 18.

[0029] Embodiment 2: Figure 2 As shown, in this embodiment, on the basis of the first embodiment, the three-way pipe A is changed into a buffer chamber. In this embodiment, the drug administration pipeline 1 and the first air supply pipeline 4 are connected through a buffer chamber 23, and the volume of the buffer chamber 23 is equivalent to the volume of the abdominal cavity; the upper part of the buffer chamber 23 is provided with a chamber cover, and the chamber cover of the buffer chamber is rotatably connected with a stirring shaft 24 extending into the buffer chamber, and the lower end of the stirring shaft is connected with a stirring impeller 25; the chamber cover of the buffer chamber is also connected with an exhaust pipe 27 and a pressure gauge 28, and a valve 22 is provided on the exhaust pipe. A heater 8 is provided on the outer side of the buffer chamber, and the heater 8 is directly set on the buffer chamber instead of being connected in series in the drug administration pipeline. The exhaust pipe 27 is connected to the vacuum pump 36, and an exhaust pump can be used. The air in the buffer chamber can be exhausted by vacuuming. The buffer chamber 23 is used to temporarily store carbon dioxide chemotherapy drug aerosol, stabilize the aerosol pressure, and make the carbon dioxide gas and aerosol mix more evenly by stirring.

[0030] In this embodiment, the bottom of the cache is provided with a first drug outlet and a second drug outlet, and the cache cover is provided with a first drug inlet and a second drug inlet, the first drug inlet and the first drug outlet are used for serial drug delivery pipelines, and the second drug inlet is connected to the first air supply pipeline; the second drug outlet is connected to a drug outlet pipe 29. During intraperitoneal chemotherapy, the aerosol vortex generated by the vortex generator enters the cache 23 through the first drug inlet, and the cache 23 is used to temporarily store carbon dioxide chemotherapy drug aerosol. The carbon dioxide pneumoperitoneum machine appropriately replenishes air through the first air supply pipeline 4 and the second drug inlet to maintain the aerosol pressure in the cache 23 at 12-15 mmHg. Under the action of the stirring impeller 25, the carbon dioxide gas and the chemotherapy drug aerosol in the cache 23 are mixed more evenly. The mixed aerosol temporarily stored in the cache 23 enters the peritoneal cavity through the first drug outlet and the drug delivery pipeline 1 to start chemotherapy. After exhausting the waste gas, the buffer chamber 23 can continuously generate new mixed working aerosol to enter the abdominal cavity. The carbon dioxide pneumoperitoneum machine always maintains the working pressure of the aerosol in the abdominal cavity at 12-15 mmHg through the first air supply pipeline 4, the buffer chamber 23 and the drug delivery pipeline 1, and acts on the peritoneal cancer tissue in a stable, efficient and uniform manner, or inhibits free cancer cells in the abdominal cavity during laparoscopic surgery.

[0031] In this embodiment, two one-way valves A13 are provided on the dosing pipeline 1, respectively located at the two ends of the vortex generator 14; a stirring motor 26 for driving the stirring shaft to rotate is provided above the buffer chamber. During the specific implementation process, the stirring shaft can also be manually controlled by a handle.

[0032] In this embodiment, the middle of the cylinder of the vortex generator 14 is provided with a second circulation inlet connected to the spiral channel, and the medicine outlet pipe 29 of the buffer chamber is connected to the second circulation inlet of the vortex generator 14; the medicine outlet pipe 29 is provided with a ball valve D19, a circulation pump 20 and a one-way valve D21; in this case, the circulation pipe of the vortex generator 14 can be omitted. During the intraperitoneal chemotherapy interval, the aerosol temporarily stored in the buffer chamber 23 can also be circulated to the vortex generator for remixing, and the carbon dioxide pneumoperitoneum machine maintains the mixed aerosol pressure in the buffer chamber 23 for preparatory work at 12-15 mmHg through the first air supply pipeline 4.

[0033] Unless otherwise stated, any technical solution disclosed in the present invention disclosed above, if it discloses a numerical range, then the disclosed numerical range is a preferred numerical range, and any technician in the field should understand that the preferred numerical range is only a numerical value with a more obvious technical effect or representative value among many implementable numerical values. Since there are too many numerical values ​​to be exhaustive, the present invention discloses some numerical values ​​to illustrate the technical solution of the present invention, and the numerical values ​​listed above should not constitute a limitation on the scope of protection of the present invention.

[0034] If the present invention discloses or involves components or structures that are fixedly connected to each other, then, unless otherwise stated, the fixed connection can be understood as: a detachable fixed connection (for example, connection using bolts or screws), and can also be understood as: a non-detachable fixed connection (for example, riveting, welding). Of course, the mutual fixed connection can also be replaced by an integrated structure (for example, manufactured by integrated molding using a casting process) (except when it is obviously impossible to use an integrated molding process).

[0035] In addition, unless otherwise stated, the terms used to indicate positional relationships or shapes in any of the technical solutions disclosed in the present invention include states or shapes that are approximate, similar, or close to them.

[0036] Any component provided by the present invention may be assembled from a plurality of separate components, or may be a separate component manufactured by an integral forming process.

[0037] The above is only a preferred embodiment of the present invention, and does not limit the present invention in other forms. Any technician familiar with the profession may use the above disclosed technical content to change or modify it into an equivalent embodiment with equivalent changes. However, any simple modification, equivalent change and modification made to the above embodiment according to the technical essence of the present invention without departing from the technical solution of the present invention still belongs to the protection scope of the technical solution of the present invention.

Claims

1. An in vitro vortex-mixing carbon dioxide chemotherapy drug aerosol generation system, characterized by: It comprises a drug administration pipeline, a drug nebulizer, an abdominal cavity and a carbon dioxide insufflator. One end of the drug administration pipeline is connected to the drug nebulizer, and the other end is connected to the abdominal cavity. A first air supply pipeline is connected between the carbon dioxide insufflator and the drug administration pipeline, and a second air supply pipeline is connected between the carbon dioxide insufflator and the abdominal cavity. A vortex generator is arranged on the drug administration pipeline.

2. The in vitro vortex-mixed carbon dioxide chemotherapy drug aerosol generation system according to claim 1, characterized in that: The drug delivery pipeline is provided with a one-way valve A, a ball valve A and a heater.

3. The in vitro vortex-mixed carbon dioxide chemotherapy drug aerosol generation system according to claim 2, characterized in that: The first air supply pipeline is provided with a ball valve B and a one-way valve C; the second air supply pipeline is provided with a ball valve C and a one-way valve B, and the first air supply pipeline is connected to the pipe section between the one-way valve A and the ball valve A on the drug delivery pipeline.

4. The in vitro vortex-mixed carbon dioxide chemotherapy drug aerosol generation system according to claim 1, characterized in that: The vortex generator includes a cylinder, a spiral channel is provided in the cylinder, an air inlet chamber communicating with the rear end of the spiral channel is provided inside the rear end of the cylinder, an air outlet chamber communicating with the front end of the spiral channel is provided inside the front end of the cylinder, a main inlet communicating with the air inlet chamber is provided at the rear end of the cylinder, and a main outlet communicating with the air outlet chamber is provided at the front end.

5. The in vitro vortex-mixed carbon dioxide chemotherapy drug aerosol generation system according to claim 4, characterized in that: The rear end side of the cylinder of the vortex generator is provided with a first circulation inlet connected to the air inlet chamber, and the front end side is provided with a circulation outlet connected to the air outlet chamber. A circulation pipe is connected between the circulation outlet and the circulation inlet, and a ball valve D, a circulation pump and a one-way valve D are provided on the circulation pipe.

6. The in vitro vortex-mixed carbon dioxide chemotherapy drug aerosol generation system according to claim 1, characterized in that: The drug administration pipeline and the first air supply pipeline are connected through a buffer chamber, and a chamber cover is provided on the upper part of the buffer chamber. The chamber cover of the buffer chamber is rotatably connected to a stirring shaft extending into the buffer chamber, and a stirring impeller is connected to the lower end of the stirring shaft; an exhaust pipe and a pressure gauge are also connected to the chamber cover of the buffer chamber, and a heater is provided on the outer side of the buffer chamber.

7. The in vitro vortex-mixed carbon dioxide chemotherapy drug aerosol generation system according to claim 6, characterized in that: The bottom of the cache bin is provided with a first drug outlet and a second drug outlet, and the cover of the cache bin is provided with a first drug inlet and a second drug inlet. The first drug inlet and the first drug outlet are used for connecting the drug delivery pipeline in series, and the second drug inlet is connected to the first air supply pipeline; the second drug outlet is connected to a drug outlet pipe, and a ball valve E is provided on the drug outlet pipe.

8. The in vitro vortex-mixed carbon dioxide chemotherapy drug aerosol generation system according to claim 6, characterized in that: The air extraction pipe is connected to the vacuum extraction device and a valve is arranged on the air extraction pipe.

9. The in vitro vortex-mixed carbon dioxide chemotherapy drug aerosol generation system according to claim 1, characterized in that: The drug nebulizer adopts a compression nebulizer, and the compressed gas inlet of the compression nebulizer is connected to a carbon dioxide high-pressure air pipe; a first drug inlet is provided on the side of the compression nebulizer, and the first drug inlet is connected to the drug storage tank through a drug supply pipe, and a peristaltic pump and a one-way valve E are provided on the drug supply pipe.

10. The in vitro vortex-mixed carbon dioxide chemotherapy drug aerosol generation system according to claim 1, characterized in that: The abdominal cavity is connected to an exhaust pipeline, and the exhaust pipeline is connected to an exhaust safety valve and an exhaust gas treatment system.

Images